Myelodysplastic and Acute Myeloid Leukemia Registry

Connect, The Myelodysplastic Syndromes (MDS), and Acute Myeloid Leukemia (AML) Disease Registry

Objective

Patients newly diagnosed (within 60 days prior to enrollment) with confirmed, primary or secondary MDS or AML will be eligible to participate.  This is a prospective, longitudinal multi-center observational study.

IRB Protocol Number

NA

Principal Investigator(s)

Brock Whittenberger, MD

Sponsor(s)

Celgene Corporation

Contact

Linda Allen, RN OCN at 406-435-7481
or lallen@billingsclinic.org